Calton & Associates’s Anavex Life Sciences AVXL Stock Holding History

Calton & Associates’s Portfolio AVXL Stock Details AVXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-250	Closed	–	–	406
2017 Q4	$0	Buy	+250	New	+$984	﹤0.01%	1479

Other funds holding AVXL

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Calton & Associates's AVXL Position: Q1 2018 in Review

Calton & Associates sold out of Anavex Life Sciences (AVXL) in Q1 2018, closing a stake of 250 shares.

Calton & Associates first reported a position in AVXL in Q4 2017 and held it in 1 quarter. The position peaked at $0 in Q4 2017. 58 funds tracked by Wall St. Rank hold AVXL as of Q1 2018.

Calton & Associates reported no remaining Anavex Life Sciences position as of Q1 2018 after selling out during the quarter.
Calton & Associates sold 250 Anavex Life Sciences shares in Q1 2018.
Calton & Associates first reported a position in Anavex Life Sciences in Q4 2017 and held it in 1 quarter.
Calton & Associates's Anavex Life Sciences position peaked at $0 in Q4 2017.
58 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q1 2018.

Based on Calton & Associates's 13F filing for Q1 2018, filed 17 Apr 2018.